Elite in Hypophosphatasia (HPP)

Wolfgang Hogler

Birmingham, ENG, GB 
Elite in Hypophosphatasia (HPP)
Birmingham, ENG, GB 
OverviewLocationsClinical Research

Overview

Wolfgang Hogler practices in Birmingham, United Kingdom. Mr. Hogler is rated as an Elite expert by MediFind in the treatment of Hypophosphatasia (HPP). His top areas of expertise are Hypophosphatasia (HPP), Rickets, Osteomalacia, Malnutrition, and Hormone Replacement Therapy (HRT).

His clinical research consists of co-authoring 144 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 19 articles in the study of Hypophosphatasia (HPP).

Gender
Male

Locations

Birmingham, ENG, United Kingdom
Other Locations
Manchester, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Open-label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin - Therapy in Pre-pubertal Children With Growth Hormone Deficiency
A Phase 3, Open-label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin - Therapy in Pre-pubertal Children With Growth Hormone Deficiency
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drugs: MOD-4023, Somatropin
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 3
View 1 Less Clinical Trial

144 Total Publications

Thanatophoric Dysplasia Type 1 Treated with Vosoritide: A Case Report.
Thanatophoric Dysplasia Type 1 Treated with Vosoritide: A Case Report.
Journal: Hormone research in paediatrics
Published: September 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hogler's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 14 Advanced Conditions
View All 58 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile